Italy launches OpportunItaly platform as pharma exports surge 54%
Italy launched the OpportunItaly digital platform at BIO 2026 to connect US investors with Italian biotech firms, following a 54% surge in pharma exports to the US to €15.7 billion in 2025. The life sciences sector accounts for over 10% of Italy's GDP, with the country leading the EU in CDMO manufacturing and patent productivity. The initiative aims to foster commercial connections through digital matchmaking and B2B services.
*this image is generated using AI for illustrative purposes only.
Italy launched the OpportunItaly digital platform at the BIO International Convention 2026 in San Diego to connect US investors with Italian biotech firms. The initiative follows a 54% surge in pharmaceutical exports to the US, which reached €15.7 billion in 2025. The life sciences sector now accounts for over 10% of Italy's national GDP, driven by the country's leadership in Contract Development and Manufacturing Organization (CDMO) manufacturing and patent productivity.
The OpportunItaly platform, a business acceleration program promoted by the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation (MAECI), serves as a digital gateway for American companies. It offers advanced digital matchmaking services, market reports, and direct access to a database of verified Italian producers. The platform features the OpportunItaly Buyers Club, where US buyers can access curated B2B matching tools and personalized support from ITA Trade Analysts.
Italy ranks 1st in the EU for CDMO manufacturing value with a 24% market share and 1st in Europe for patent productivity. The US remains Italy's primary destination market, with biotech exports reaching €3.2 billion. Life sciences represent the single largest component of Italian high-tech exports to the US at 36.8%. Over the past five years, Italy's global life sciences exports have increased by 60%, totaling €52 billion annually.
The Italian Pavilion at BIO 2026 features 20 exhibitors, including Accelera, BiomimX, Butterfly Decisions, Euromed Pharma, Fondazione Ri.MED, InSilicoTrials, IRBM, Masotti Cassella, Menarini Biotech, Regulatory Pharma Net (RPN), Società Italiana Brevetti, Soffieria Bertolini, and Takis. The delegation is organized by ITA in collaboration with MAECI, the Ministry of Enterprises and Made in Italy (MIMIT), and supported by Farmindustria, Federchimica Assobiotec, Invitalia, and Invest in Italy.
The convention also features the Montalcini Global Biotech Tour on June 22, organized in collaboration with the Consulate General of Italy in Los Angeles. The event includes a panel discussion moderated by Clarissa Ceruti, Executive Director of ISSNAF, with speakers from CounterX Therapeutics, Euromed Pharma, the La Jolla Institute for Immunology, and Menarini Biotech. Opening remarks will be delivered by Raffaella Valentini, Consul General of Italy in Los Angeles, Francesca Mauri of the ITA Office in Los Angeles, and Lombardy Region Councilors Guido Guidesi and Guido Bertolaso.
Key Italian Life Sciences Metrics
| Metric | Value |
|---|---|
| Pharma exports to US (2025) | €15.7 billion |
| Growth in pharma exports to US | +54% |
| Biotech exports to US | €3.2 billion |
| Share of high-tech exports to US | 36.8% |
| Global life sciences exports (annual) | €52 billion |
| 5-year export growth | +60% |
| Share of national GDP | >10% |
| EU CDMO market share | 24% |
How will the OpportunItaly platform impact the pace of cross-border M&A activity between US pharmaceutical giants and Italian biotech firms?
Can Italy sustain its 24% EU market share in CDMO manufacturing amidst increasing competition from emerging markets in Asia?
What regulatory hurdles might US investors face when integrating with Italian biotech companies despite the new digital matchmaking tools?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
